Visiongain Publishes Amyotrophic Lateral Sclerosis Treatment Market Report to 2031

12 March 2021
Pharma

Visiongain has published a new report on Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios.

Global Amyotrophic Lateral Sclerosis Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on Amyotrophic Lateral Sclerosis Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Amyotrophic Lateral Sclerosis Treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers
Growing Occurrence of Amyotrophic Lateral Sclerosis
According to the statistics by the National Institute of Neurological Disorders and Stroke, following gradual paralysis, people with Amyotrophic Lateral Sclerosis often die from respirational failure within 3 to 5 years. NINSD also indicated that between the two types of Amyotrophic Lateral Sclerosis, the sporadic type is the typical form of the disease, estimating for 90% to 95% of all incidence took place in the U.S. while the familial type of the disease accounts for the rest.

Familial Amyotrophic Lateral Sclerosis (FALS) is genetic, where there is a 50% chance of receiving the hereditary mutation for each progeny and ultimately causing the disease. In 25-40% of the patient affected by the FALS, the fault is generally found in the C9ORF72 gene. Alteration in this gene also causes a disorder known as frontotemporal dementia (FTD), which may develop along with Amyotrophic Lateral Sclerosis as a comorbidity known as ALS-FTD. Therefore, the growing incidence rate of ALS demands proper treatment to avoid any mortality, in turn, propelling the target industry growth.

Increasing Research and Developmental Activities for Treatment of ALS Disorder
Though there is no direct treatment for Amyotrophic Lateral Sclerosis, however treatments such as pills and stem cell therapies can aid in the managing of the indications, prevent unnecessary problems, and help to slow down the disease advancement.

Due to the great number of unmet requirements, companies operating in the market are focusing on the invention and technological developments in treatment options which force the growth of the ALS treatment market worldwide. The Amyotrophic Lateral Sclerosis clinical pipeline is robust and diverse, with late-stage programs which target at improving immune modulation, muscle function, and neuroprotection, along with mid or early-stage stem-cell therapies, gene therapy approaches, and immune-targeting agents and specialists, struggle that treatments joining multiple mechanisms of action could embrace major scientific promise in the management of ALS disease. Consequently, a substantial profitable opportunity exists for inventors that can overcome the technical and clinical issues hindering the path to governing endorsement for the treatment of ALS. For instance, In April 2018, Target ALS introduced new research that links the CReATe Consortium, 10 pharmaceutical companies, and the Muscular Dystrophy Association, to authorize the most promising Amyotrophic Lateral Sclerosis biomarker candidates, and instantaneously make all outcomes largely available to the globally ALS research community.

Market Opportunities

Availability of Funding for Research
Rising research & development activities and funding from government and numerous public-private organizations in stem cell studies are eventually contributing to the Amyotrophic Lateral Sclerosis Treatment market growth. The rising government initiatives in emerging economies, the existence of a huge number of drug product pipelines, and its therapeutic applications are the crucial factors fueling the demand for Amyotrophic Lateral Sclerosis Treatment, hence, aiding the target industry growth.

Competitive Landscape
Key players operating in the global Amyotrophic Lateral Sclerosis Treatment market are Sun Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, BrainStorm Therapeutics, Corestem, Biogen Inc., Biohaven Pharmaceutical, AB Science, F.Hoffmann-La Roche AG, Otsuka Pharmaceutical Co., Ltd., and Ionis Pharmaceuticals, Inc.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Amyotrophic Lateral Sclerosis Treatment market. For instance, In May 2019, Biogen Inc. publicized the short-term outcomes of phase 1 and 2 study of tofersen, which may be the possible treatment of ALS in elder people with a certain superoxide dismutase 1 (SOD1) alteration.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever